-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Aprea Therapeutics recently announced the positive results of a phase 2 clinical trial that is evaluating eprenetapopt (APR-246) in combination with azacitidine (AZA) for TP53 mutant myelodysplastic syndrome (MDS) and acute myelodysplastic syndromes.
In addition to eprenetapopt, Aprea also has a drug APR-548, which is a new generation of small molecule p53 reactivator, which shows high oral bioavailability in TP53 mutant cancer cell lines, and has enhanced efficacy compared with eprenetapopt.
Original source: Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML
Original title: New drug for p53 target! eprenetapopt+azacitidine in the treatment of TP53 mutant myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): a significant effect!